Abstract
Recent regulatory guidance suggests that drug metabolites identified in human plasma should be present at equal or greater levels in at least one of the animal species used in safety assessments (MIST). Often synthetic standards for the metabolites do not exist, thus this has introduced multiple challenges regarding the quantitative comparison of metabolites between human and animals. Various bioanalytical approaches are described to evaluate the exposure of metabolites in animal vs. human. A simple LC/MS/MS peak area ratio comparison approach is the most facile and applicable approach to make a first assessment of whether metabolite exposures in animals exceed that in humans. In most cases, this measurement is sufficient to demonstrate that an animal toxicology study of the parent drug has covered the safety of the human metabolites. Methods whereby quantitation of metabolites can be done in the absence of chemically synthesized authentic standards are also described. Only in rare cases, where an actual exposure measurement of a metabolite is needed, will a validated or qualified method requiring a synthetic standard be needed. The rigor of the bioanalysis is increased accordingly based on the results of animal:human ratio measurements. This data driven bioanalysis strategy to address MIST issues within standard drug development processes is described
Keywords: Drug metabolite safety assessment, HPLC/MS/MS, MIST, metabolite quantitation, peak area ratio, radiometric quantitation, bioanalytical, proton NMR, mercapturic acids, methylcatechols
Current Drug Metabolism
Title: Addressing MIST (Metabolites in Safety Testing): Bioanalytical Approaches to Address Metabolite Exposures in Humans and Animals
Volume: 12 Issue: 6
Author(s): Hongying Gao and R. Scott Obach
Affiliation:
Keywords: Drug metabolite safety assessment, HPLC/MS/MS, MIST, metabolite quantitation, peak area ratio, radiometric quantitation, bioanalytical, proton NMR, mercapturic acids, methylcatechols
Abstract: Recent regulatory guidance suggests that drug metabolites identified in human plasma should be present at equal or greater levels in at least one of the animal species used in safety assessments (MIST). Often synthetic standards for the metabolites do not exist, thus this has introduced multiple challenges regarding the quantitative comparison of metabolites between human and animals. Various bioanalytical approaches are described to evaluate the exposure of metabolites in animal vs. human. A simple LC/MS/MS peak area ratio comparison approach is the most facile and applicable approach to make a first assessment of whether metabolite exposures in animals exceed that in humans. In most cases, this measurement is sufficient to demonstrate that an animal toxicology study of the parent drug has covered the safety of the human metabolites. Methods whereby quantitation of metabolites can be done in the absence of chemically synthesized authentic standards are also described. Only in rare cases, where an actual exposure measurement of a metabolite is needed, will a validated or qualified method requiring a synthetic standard be needed. The rigor of the bioanalysis is increased accordingly based on the results of animal:human ratio measurements. This data driven bioanalysis strategy to address MIST issues within standard drug development processes is described
Export Options
About this article
Cite this article as:
Gao Hongying and Scott Obach R., Addressing MIST (Metabolites in Safety Testing): Bioanalytical Approaches to Address Metabolite Exposures in Humans and Animals, Current Drug Metabolism 2011; 12 (6) . https://dx.doi.org/10.2174/138920011795713661
DOI https://dx.doi.org/10.2174/138920011795713661 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of brain tissue binding and plasma protein binding of drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
Safety evaluation of vaccine combination
Vaccine combination safety evaluation is a critical field within immunology and public health that focuses on assessing the safety and efficacy of combining different vaccines to maximize protection against various diseases while minimizing potential adverse effects. This process is significant because it ensures that vaccines can be administered together without ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) Meet Our Editorial Board Member
MicroRNA Anti-Allergic and Antioxidant Activity of 5-Hydroxy-3,6,7,3’,4’- Pentamethoxy Flavone Isolated from Leaves of Vitex negundo
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Techniques and Strategies to Analyze Neural Progenitor Cell Migration
Current Pharmaceutical Biotechnology Both OB Folds of Single-Stranded DNA-Binding Protein Are Essential for Its ssDNA Binding Activity in Deinococcus radiodurans
Protein & Peptide Letters Helminth Products as a Potential Therapeutic Strategy for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Recognition of Fungal Pathogens by Toll-Like Receptors
Current Pharmaceutical Design Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets Study the Effect of PG E1 and PGF2α on Male Rat Reproductive Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets COVID-19 and L-arginine Supplementations: Yet to Find the Missed Key
Current Protein & Peptide Science Recent Trends and Applications in 3D Virtual Screening
Combinatorial Chemistry & High Throughput Screening Computer Prediction of Cardiovascular and Hematological Agents by Statistical Learning Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Immunology of VIP: A Review and Therapeutical Perspectives
Current Pharmaceutical Design Natural and Semi synthetic Antimalarial Compounds: Emphasis on the Terpene Class
Mini-Reviews in Medicinal Chemistry Vascular Effects of Ambient Pollutant Particles and Metals
Current Vascular Pharmacology Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Runx2/Cbfa1: A Multifunctional Regulator of Bone Formation
Current Pharmaceutical Design A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging